国产成人精品高清久久_好姑娘影视在线观看高清_99久久久久久久久_欧美涩涩网_久久国产精品91_9色网站

德國Micromet?
Micromet創(chuàng)建于德國，總部現(xiàn)設(shè)在馬里蘭州的Rockville，該公司正在開發(fā)一款試驗性血癌治療藥物，目前處在中期試驗階段。

Micromet was founded in 1993 by a small team of entrepreneurial scientists from the University of Munich with a firm belief in the potential of T cell based therapies to treat cancer. Their vision was to develop a new class of drugs that mobilize T cells, the body's most potent killer cells, enabling them to detect and destroy normally unrecognizable cancer cells. Within a few short years, the Company demonstrated the clinical potential of its technology, referred to as BiTE? (Bi-specific T cell engager), with the publication of compelling results from a Phase 1 trial of its BiTE antibody Blinatumomab (MT103) in patients with non-Hodgkin's lymphoma. Micromet began trading on the Nasdaq Global Market under the symbol MITI following a May 2006 reverse merger with California-based CancerVax.

Today Micromet is an integrated biopharmaceutical company with a pipeline of promising drug candidates, a clinically validated technology platform and strong BiTE antibody partnerships with industry leaders.

Micromet Today
Our goal is to discover, develop and commercialize breakthrough therapies with the potential to deliver meaningful clinical benefit to oncology patients. Our lead product candidate blinatumomab (MT103) has demonstrated single-agent activity in both adult and pediatric patients with acute lymphoblastic leukemia and is now the subject of a broad based development program in this disease setting. MT110, our second BiTE antibody, is currently in development in patients with advanced solid tumors. We are also advancing a pipeline of promising preclinical candidates and have robust research capabilities fuelling our long-term growth.

Micromet is headquartered in Rockville, Maryland with a research facility in Munich, Germany.
?